Drug interactions
Inotuzumab + Ipratropium-salbutamol
Severity: Moderate
Inotuzumab and Ipratropium-salbutamol: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Inotuzumab ozogamicin is associated with QT prolongation, and salbutamol can contribute through hypokalemia and cardiac stimulation. Combined use may increase arrhythmia risk, especially with electrolyte disturbances.
What this interaction means in plain words
Inotuzumab and Ipratropium-salbutamol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive QT interval prolongation, with beta-agonist-related hypokalemia.
What to do
Obtain ECG and electrolytes at baseline and during inotuzumab therapy, and correct potassium and magnesium. Limit salbutamol to what is clinically needed.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Inotuzumab and Ipratropium-salbutamol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipratropium-salbutamol
Frequently asked questions
Can I take Inotuzumab with Ipratropium-salbutamol?
MediHelp rates the interaction as moderate. Inotuzumab and Ipratropium-salbutamol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Inotuzumab ozogamicin is associated with QT prolongation, and salbutamol can contribute through hypokalemia and cardiac stimulation. Combined use may increase arrhythmia risk, especially with electrolyte disturbances.
How serious is the interaction between Inotuzumab and Ipratropium-salbutamol?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain ECG and electrolytes at baseline and during inotuzumab therapy, and correct potassium and magnesium. Limit salbutamol to what is clinically needed.
What other medicines interact with Ipratropium-salbutamol?
MediHelp also lists interactions of Ipratropium-salbutamol with, for example, Amisulpride, Arsenic trioxide, Carvedilol. The full list is on the Ipratropium-salbutamol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
